ImmuCell (NASDAQ:ICCC) Share Price Passes Above 200 Day Moving Average - Here's What Happened

Key Points

• ImmuCell's stock price has recently crossed above its 200-day moving average, trading at $6.65 after hitting a high of $7.02.
• For the most recent quarter, ImmuCell reported $0.16 earnings per share with revenues of $8.07 million, despite having a negative return on equity.
• Institutional investors hold 13.47% of ImmuCell's stock, with notable increases in holdings by firms such as Northern Trust Corp and Geode Capital Management.

ImmuCell Corporation (NASDAQ:ICCC - Get Free Report) shares passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $5.74 and traded as high as $7.02. ImmuCell shares last traded at $6.65, with a volume of 10,965 shares.

ImmuCell Price Performance

The business has a fifty day moving average price of $6.53 and a 200-day moving average price of $5.76. The company has a current ratio of 4.12, a quick ratio of 2.21 and a debt-to-equity ratio of 0.30. The stock has a market capitalization of $55.14 million, a PE ratio of 32.11 and a beta of 0.30.

ImmuCell (NASDAQ:ICCC - Get Free Report) last released its earnings results on Thursday, August 14th. The biotechnology company reported $0.06 earnings per share for the quarter. ImmuCell had a return on equity of 6.37% and a net margin of 6.23%. The company had revenue of $6.45 million during the quarter.

Institutional Investors Weigh In On ImmuCell

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC lifted its stake in shares of ImmuCell by 4.2% in the 2nd quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company's stock valued at $500,000 after acquiring an additional 2,907 shares during the last quarter. Citadel Advisors LLC bought a new stake in shares of ImmuCell in the 4th quarter valued at about $149,000. Northern Trust Corp lifted its stake in shares of ImmuCell by 51.0% in the 4th quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company's stock valued at $229,000 after acquiring an additional 14,982 shares during the last quarter. Finally, Dauntless Investment Group LLC bought a new stake in shares of ImmuCell in the 4th quarter valued at about $676,000. Institutional investors own 13.47% of the company's stock.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.